Ferring Pharmaceuticals is a research-driven biopharmaceutical company dedicated to researching, developing and marketing innovative treatments in a number of key therapeutic areas including maternal health and reproductive health, as well as urology and gastroenterology. Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals operate from nearly 60 countries. Ferring Canada started its operations in 1989 with just three employees. Today, the company employs nearly 90 employees and sees considerable growth ahead as it continues to bring valuable new products to the Canadian marketplace. Ferring Canada is committed to providing innovative medicines that will help Canadians have a better quality of life in the years to come. To learn more about Ferring or its products, visit [www.ferring.ca](http://www.ferring.ca).

For information or educational support please contact:
[Sonia.Kahng@ferring.com](mailto:Sonia.Kahng@ferring.com) C. 604.966.1469
CERVIDIL®
PROSTAGLANDIN E2/DINOPROSTONE

- The **first and only** dinoprostone vaginal insert for the induction of cervical ripening.\(^1\)*
  - Dinoprostone - an effective molecule for initiation and/or continuation of cervical ripening\(^1\)
  - Single-dose, **continuous-release** retrievable vaginal insert\(^1\)
  - **Easy and reliable** removal of the insert\(^1\)

*Comparative clinical significance is unknown.
DURATOCIN® (carbetocin) is indicated for the prevention of postpartum haemorrhage by controlling uterine atony. Please consult the DURATOCIN room temperature stable vial Product Monograph at: https://www.ferring.ca/en/products/reproductive-medicine-and-maternal-health/maternal-health-products/ for important information on contraindications, warnings, precautions, adverse reactions, drug interactions, dosing and conditions of clinical use. Or contact Ferring’s Medical Information department by phone at 1-866-384-1314 or email to CA0-Medicalinformation@ferring.com

©2020 Ferring Inc. All rights reserved. DURATOCIN® is a registered trademark of Ferring B.V.

**Strength:**
- 100 mcg/mL

**Pack size/format:**
- 5 x 1 mL vials, single use
- 5 x 1 mL ampoules, single use

**Storage:**
- Room temperature
- Refrigeration

**Administration:**
- Vaginal delivery – IM or IV, or Caesarean delivery – IV

**Labelling feature:**
- Unit dose labelling

**DIN:**
- 02496526
- 02231593

**UPC:**
- 779170192852
- 779170191008

**McKesson Order #:**
- 153026
- 153346

---

- **NEW room temperature stable vials**
- **Effectively Immediately**

- Now indicated for **vaginal**, as well as **caesarean** deliveries
- Administered via **IM** or **IV**
- In **room temperature stable vials**